09 Sep Why Sagging Skin And Lost Volume Need Different Treatments
There is a moment, usually somewhere in your forties, when the face in the mirror stops matching the one in your head. The jawline is softer. Something around the mouth has slipped. The instinct is to go looking for a treatment, and there is no shortage. Better to start one step earlier and ask what has actually changed, because faces change in three fairly separate ways, and each answers to a different tool. Volume loss is one. Muscle and movement is another. Laxity is the third, where the skin itself has lost its firmness, and it is the one most people are reading about when they start looking into Ultherapy in Singapore and other energy-based tightening options. Confusing the three is a costly mistake, because the right tool aimed at the wrong problem does very little. According to the AAD (American Academy of Dermatology), ultrasound skin tightening works by delivering focused energy beneath the skin's surface to stimulate collagen production, with results that develop gradually over several months and suit mild to moderate skin laxity.
[caption id="attachment_75918" align="aligncenter" width="500"]
Photo by Gustavo Fring[/caption]
Dr. Petukhova[/caption]
Dr. Mosnaim[/caption]
Dr. Giselle Mosnaim MD MS FACAAI
Allergist
Division of Allergy and Immunology
Department of Medicine
Northshore University Health System
REMIX-1/-2 Investigator
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Chronic spontaneous urticaria is a debilitating condition significantly affecting patient quality of life and is characterized by the presence of itch, hives, and/or angioedema (swelling) lasting for greater than 6 weeks, without identifiable trigger. Second-generation H1-antihistamines at standard doses are recommended as first-line treatment for patients with chronic spontaneous urticaria, and can be up-dosed to 4 times the standard dose. However, over 50% of patients continue to have symptoms despite this therapy. Both Remibrutinib and Dupilumab are FDA-approved for the treatment of chronic spontaneous urticaria in adult patients (Remibrutinib ≥ 18 years old and Dupilumab ≥ 12 years old) who remain symptomatic despite second-generation H1-antihistamine treatment.
The RECLAIM study is an ongoing head-to-head randomized controlled trial comparing the efficacy of Remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, and Dupilumab, an injectable anti-interleukin-4 and anti-interleukin-13 inhibitor, at early timepoints (4 weeks and earlier) when administered as an add-on therapy in adults with moderate to severe chronic spontaneous urticaria inadequately controlled by second-generation H1-antihistamines.